

3rd Workshop
Eurordis Round Table of Companies

*“Rare Disease Clinical Trials:
Ensuring Fruitful Collaborations between Sponsors & Patient Organisations”*

November 21st 2005

9.00 am-5.40 pm

Fundació Doctor Robert- UAB Casa Convalescència
Barcelona- Spain

8.30 am Welcome-Coffee

<i>Morning Session co-chaired by:</i>			
<i>Prof. Bruno Flamion (chair of the CHMP- SAWP)-Prof. Josep Torrent-Farnell (Fundació Doctor Robert-Chairperson of the COMP)</i>			
	Topic	Speaker	Institution / Position
9.00 am	Welcome & Introduction	Prof. Lluís Ferrer i Caubet Mr Yann Le Cam	-President of the Universitat Autònoma de Barcelona (UAB) -Chief Executive Officer of Eurordis
9.05 am	Sponsors & Patients' Groups: an Uncommon Collaboration. Expectations and Fears of Industry	Mr Kennet Rooth	Country Manager, Swedish Orphan AB. (SE)
9.20 am	Sponsors & Patients' Groups: an Uncommon Collaboration. Expectations and Fears of Academic Clinical Research	Prof. Christian Gluud	Head of the Copenhagen Trial Unit, Copenhagen University Hospital-ECRIN (European Clinical Research Infrastructures Network) (DK)
9.35 am	PO Commitment vs. Sponsors' Responsibility: Shared Rules or Regulation ?	Dr Phillippe Vella	Head of the Trial Unit, AFSSAPS (French Agency for the Safety of Health Products) (FR)
9.50 am	NORD's Role in Clinical Development for Rare Diseases in the USA	Mrs Mary Dunkle	Vice President of Communications, NORD (National Organization for Rare Disorders) (USA)
10.05-10.30	<i>Coffee break</i>		
10.30 pm	Individual vs. Collective "Interest": the Respective Roles of Ethics Committees and Patient Organisations in Clinical Development.	Mr Francis P.Crawley	Director General, Good Clinical Practice Alliance (BE)
10.50 am	The Need of a European Framework for Collaboration: the Eurordis Charter	Mrs Flaminia Macchia	European Public Affairs Officer, Eurordis (BE)
11.20 am	Debate <i>With panellists</i>		
1.00 pm	Lunch		

3rd Workshop
Eurordis Round Table of Companies

*“Rare Disease Clinical Trials:
Ensuring Fruitful Collaborations between Sponsors & Patient Organisations”*

November 21st 2005

9.00 am-5.40 pm

Fundació Doctor Robert- UAB Casa Convalescència
Barcelona- Spain

<i>Afternoon Session chaired by:</i>			
<i>Dr Marlene E. Haffner (Director, Office of Orphan Products Development, FDA)-Dr Fernando de Andrés Trelles (Spanish Medicines Agency, COMP member, EMEA)</i>			
	Topic	Speaker	Position /Institution
2.30 am	Patient Organisations' Expertise in “Document” Rewriting (content and/or form)	Dr Jean Genève	<i>Head of the BECT/FNCLCC (Clinical Research Department, National Comprehensive Cancer Center Federation) (FR)</i>
2.50 am	Patient Organisations' Role in Clinical Trials Development (case stories, lessons)	Mr Nikos Dedes	<i>Chair of the EATG (European Aids Treatment Group) (GR)</i>
3.10 pm	Role of Patients in Clinical Trials. From Participation to Collaboration: the Need for Training	Mrs Dominique Donnet-Kamel and Dr Marga Pla	<i>-Manager Inserm Office for Patient Organisations, INSERM (National Institute for Public Health and Medical Research) (FR) -Director of the Master of Qualitative and Participative Research, UAB (SP)</i>
3.30 pm	The FDA's Experience with Patient Organisations in Clinical Trials	Mr Richard Klein	<i>Public Health Specialist, Office of Special Health Issues, FDA (Food and Drug Administration) (USA)</i>
3.45 pm	<i>Coffee break</i>		
4.00 pm	Keys for Ensuring Fruitful Collaborations between Sponsors and Patient Organisations.	Panel of representatives from Patient Organisations and Industry	<i>-Mrs Christine Lavery, Chief Executive, MPS Society (UK) -Dr Andreas Reimann, CEO Mukoviszidose.eV.(GE) -Dr René Goedkoop, VP Clinical Development, Apoxis S.A.(CH) -Mrs Claudia Hirawat, VP Corporate Development, PTC Therapeutics (USA)</i>
4.20 pm	Debate <i>With panellists</i>		
5.30 pm	Closing speech <i>Dr Maria Teresa Pagés, General Director of Pharmacy, Ministry of Health and Consumer Affairs (SP)</i>		
5.40 pm	Adjourned		